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Abstract 
Among the applications of fullerene technology in health sciences the expanding field of 
magnetic resonance imaging (MRI) of molecular processes is most challenging. Here we 
present the synthesis and application of a GdxSc3-xN@C80-BioShuttle-conjugate referred to as 
Gd-cluster@-BioShuttle, which features high proton relaxation and, in comparison to the 
commonly used contrast agents, high signal enhancement at very low Gd concentrations. This 
modularly designed contrast agent represents a new tool for improved monitoring and 
evaluation of interventions at the gene transcription level. Also, a widespread monitoring to 
track individual cells is possible, as well as sensing of microenvironments. Furthermore, 
BioShuttle can also deliver constructs for transfection or active pharmaceutical ingredients, 
and scaffolding for incorporation with the host's body. Using the Gd-cluster@-BioShuttle as 
MRI contrast agent allows an improved evaluation of radio- or chemotherapy treated tissues. 
Key words: inverse Diels Alder Reaction, BioShuttle, fullerenes, gadolinium, intravital Imaging; 
nitridecluster fullerenes; intracellular imaging, Magnetic Resonance Imaging (MRI), metallofulle-
renes, Molecular Imaging; Rare Earth compounds 
Introduction 
Since Kraetschmer’s pioneering work in the 
synthesis of fullerenes[1, 2] continued the initial work 
by Kroto, Smalley and Curl[3-5], speculations for 
possible applications were tremendous, after the suc-
cessful large-scale synthesis and the characterisation 
of the structural and electronic properties of the 
fullerenes.[6,7] Endohedral fullerenes (endofullere-
nes) can trap atoms, ions or clusters, such as the 
Gadolinium ions (Gd3+) inside their inner sphere. In 
most endofullerenes a charge transfer from the in-
corporated species unto the cage occurs, resulting in a 
more polar molecule.[8]  
The hydrophobic character of fullerenes was 
compromised by covalent addition of hydrophilic Int. J. Med. Sci. 2010, 7 
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groups at the cage’s surface. The synthesis of such a 
fullerenol was first reported by Chiang et al. in 
1992.[9] The continuous attention which fullerenoles 
attracted since then was largely due to their hydroxyl 
groups resulting in increased water solubility. The 
modification of lipophilic fullerenes to become wa-
ter-soluble was used for endohedral metallofullerenes 
permitting multi-faced applications also dedicated for 
industrial use.[10, 11] Such molecules were selected to 
carry active agents or diagnostics into the organism. 
Their paramagnetic properties differ dramatically 
from the commonly used diagnostic routine tools, in 
which Gd3+ is bound to chelating agents like diethyl-
enetriaminepentaacetic acid (DTPA) (Magnevist®), or 
diethylenetriamine- 
pentaacetate-bis-(methylamide) (Omniscan®), or 
1,4,7-tris-(carbonyl-methyl)-10-(2’-hydroxypropyl)-1,4
,7,10-tetraazacyclodecane (Prohance®).[12, 13]  
Biochemical safety studies for adverse reactions 
such as nephrogenic fibrosis by using Gd-based in-
travasal contrast agents are suggestive.[14] In order to 
meet these higher requirements for intracellular 
magnetic resonance tomography (MRT) contrast 
agents, the development of functional molecules must 
feature both: the complete lack of Gd3+ ion-release 
under metabolic processes and no detection by the 
reticular-endothelial system (RES). Such contrast 
agents (CA) have the potential for a successful 
real-time  in vivo imaging of intracellular processes. 
The development of water-soluble fullerenes with 
surface modifications like polyamido-amine den-
drimers bearing cyclodextrin (CD) or polyethylene 
glycol (PEG) and Gd-metallofullerenes 
[Gd@C82(OH)n, Gd-fullerenoles] seems to be a feasible 
approach for the use as a diagnostic tool in MRI.[15] 
However, there is evidence that Gd@C82(OH)n tends 
to be entrapped in the RES by forming large particles 
interacting with plasma components like albumin,[16] 
whereas Gd@C60[C(COOCH2CH3)2]10  lacks an accu-
mulation in the RES system.[17] [18] [19, 20] Here we 
focus on the selective development of nitride cluster 
fullerenes of Gd (and additional rare-earth elements 
featuring dipoles like Yttrium [Yt], Scandium [Sc]), 
such as GdnSc3-nN@C80n[21], which was recently 
characterized by the Dunsch group.[22] We consid-
ered these molecules for molecular imaging (MI) to 
depict morphological structures in an outstanding 
manner. MI is defined as the characterization and 
measurement of biological processes at the cellular 
and molecular level.[23] At present the rapidly 
emerging field of successful MI is represented by po-
sitron emission tomography (PET)[24], possibly com-
bined with computer tomography (CT)[25] or com-
bined with single photon emission computed tomo-
graphy (SPECT)[26] as well as bioluminescent 
(Blm)[27] and fluorescent imaging (Flm)[28]. Both 
modalities are still restricted to small-animal use.[29] 
While MRT reveals morphological structures in soft 
tissue with low intrinsic sensitivity, the sensitivity of 
PET is unmatched but hampered by the dependence 
on suitable PET tracers. Its disadvantages include 
non-detectable “low grade” tumors, false-positive 
results and radiation exposure.  
Requirements for successful intracellular imag-
ing with MRT are a perspicuous signal and a suffi-
cient accumulation of contrast agent (CA) within the 
target cells. There are numerous approaches[30, 31] 
but further developments of MR contrast agents with 
new properties are indispensable. All CAs used so far 
including the prospective GdxSc3-xN@C80 offer one 
feature in common: they are not able to penetrate the 
cellular membranes and their use is restricted to the 
blood stream and the interstitial space. The use of 
transfection agents facilitating the passage of 
Gd-containing endofullerenes across the cell mem-
brane into the cytoplasm was described [15] but is 
critical, or even toxic. 
To circumvent these biological hurdles we pur-
sued another solution for our „cell-nucleus imaging“. 
For a successful intracellular and intranuclear MRI we 
covalently linked GdxSc3-xN@C80 molecules with both 
the nuclear address (NLS) derived from SV40 
T-antigen[32], which in turn is linked via a disul-
fide-bridge to a peptide facilitating the passage across 
cell membranes (CPP)[33]. This is our BioShut-
tle-conjugate resulting in a Cell Nucleus 
(NLS)-GdxSc3-xN@C80. For simplification in the text it 
is called Gd-cluster@-BioShuttle utilizing the cyto-
plasmically located importins, classified as substrates 
for the active RAN-GDP system, mediating an effi-
cient transport of the GdxSc3-xN@C80 cargo into cell 
nuclei.[34]  
To build such conjugates we improved methods 
for rapid and complete ligation of hydrophobic 
molecules like fullerenes (and especially their func-
tionalized derivatives) to carrier molecules. In our 
studies, the Diels-Alder-Reaction (DAR) turned out to 
be an applicable ligation method, but the reverse re-
action proved to be restrictive and unsatisfactory.[35] 
The use of the “DAR with an inverse electron demand 
(DARinv)” can circumvent these drawbacks and has 
been accurately described.[36-38]  
In this paper, we exemplary demonstrate a suc-
cessful intracellular MRI through a novel 
CA-delivery. Due to its higher sensitivity an imaging 
of previously non-detectable micro-metastases and 
cell trafficking patterns is possible. Int. J. Med. Sci. 2010, 7 
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Chemical Procedures 
The synthesis and isolation of the GdxSc3-xN@C80 
cluster fullerenes has been described elsewhere.[22] 
All chemical reactions and procedures were carried 
out under normal atmosphere conditions. The 
GdxSc3-xN@C80, other educts, all solvents for chemical 
syntheses, fetal calf serum (FCS) and glutamine were 
purchased from Sigma-Aldrich, Germany or BACR, 
Karlsruhe, Germany. The chemicals used for peptide 
synthesis and purification were purchased from Roth, 
Germany. The solvents were of reagent grade and 
used without further purification. Amino acids, de-
rivatives and coupling agents were purchased from 
Merck Bioscience, Germany. Cleavage reagents were 
from Fluka-Sigma-Aldrich, Buchs, Switzerland. RPMI 
cell culture medium was purchased from Invitrogen, 
Karlsruhe, Germany. 
For the synthesis of the 
GdxSc3-xN@C80-BioShuttle we used combined chemi-
cal methods: functional modules, the derivatized 
endofullerene cargo as well as the peptide-based 
modules of the NLS address and the transmembrane 
transport component were added by solid phase pep-
tide synthesis (SPPS).[39, 40] The ligation of the CA 
cargo was carried out with a special form of the Diels 
Alder Reaction (DAR), the Diels Alder Reaction with 
inverse electron demand (DARinv) which is the basis 
for the “Click Chemistry”. The coupling of the 
GdxSc3-xN@C80  8 cargo to the spacer follows estab-
lished procedures, which after the reaction with the 
Reppe-anhydride acts as the dienophile. The diene 
(tetrazine) is introduced to the NLS module. Details of 
the preparation processes are given elsewhere.[41]  
In order to facilitate the transfer of the 
GdxSc3-xN@C80 across cell membranes we used as cell 
penetrating peptide the fragment of the HIV-1-Tat 
protein 'GRKKRRQRRRPPQ'[42] representing resi-
dues 48-58.  
The following conjugates were investigated (Ta-
ble 1). 
 
 
 
 
 
 
Table 1:  The modular structure of the Gd-Cluster@-BioShuttle. The module responsible for the transmem-
brane transport (right column) connects the NLS with the CPP via a cleavable sulfur bridge. The spacer harboring a di-
enophile-section between the NLS and the GdxSc3-xN@C80 acts as docking station for different substances, which possesses 
diene-structures.  
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Syntheses and conjugationes of the modules for 
the Gd-Cluster@-BioShuttle  
Synthesis of the mixed metal nitride cluster fullerene 
GdxSc3-xN@C80 
GdxSc3-xN@C80 (x = 1, 2) were produced by a 
modified Kraetschmer-Huffmann DC arc-discharge 
method which the addition of NH3 (20 mbar) as de-
scribed.[43, 44] Briefly, a mixture of Gd2O3 and Sc2O3 
(99.9%, MaTeck GmbH, Germany) and graphite 
powder were used (molar ratio of Gd : Sc: C = 1 : 1 : 
15). After DC arc discharge, the soot was 
pre-extracted by acetone and further Soxh-
let-extracted by CS2 for 20 h. Fullerenes were isolated 
by a two-step HPLC. In the first step, running in a 
Hewlett-Packard instrument (series 1050), a linear 
combination of two analytical 4.6 × 250 mm Bucky-
prep columns (Nacalai Tesque, Japan) was applied 
with toluene as eluent. The second-stage isolation was 
performed by recycling HPLC (Sunchrom, Germany) 
on a semi preparative Buckyprep-M column (Nacalai 
Tesque, Japan) with toluene as eluent. An UV detector 
set to 320 nm was used for fullerene detection in both 
stages. The purity of the isolated products was tested 
by LD-TOF MS analysis running in both positive- and 
negative-ion modes (Biflex III, Bruker, Germany). 
Synthesis of the diene compound N-(2-Aminopropyl)-4- 
(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)benzamide (4) 
4-(6-(pyrimidine-2-yl)-1,4-dihydro-1,2,4,5-tetrazi
ne-3-yl)benzoic acid 3 was prepared from 
2-pyrimidinecarbonitrile 1 and p-cyano benzoic acid 2 
by reaction with 85% hydrazine. After purification by 
recrystalisation the dihydrotetrazine was then oxi-
dized with nitric-acid to the tetrazine derivative fol-
lowing the known procedure[45] as shown in Figure 1 
/scheme 1. The tetrazine derivative was converted 
with thionyl chloride under standard conditions to 
the corresponding acidic chloride. To a suspension of 
this acid chloride (2 mmol) in 20 ml CH2Cl2, a solution 
of 3-amino butyric acid-tert-butyl-ester (2mmol) and 
Hunig’s base (2 mmol) in 10 ml CH 2Cl2 was slowly 
added at 0–5°C. The resulting deeply colored solution 
was maintained at room temperature for 4 h. Then the 
organic phase was washed with water, followed by 
1N-HCl and again water. The organic layer was dried 
over Na2SO4 and evaporated. The resulting residue 
was chromatographed on silicagel by elution with 
chloroform/ethanol (9 : 1) and further purified by 
recrystallization from acetone. The yield was 50–70% 
depending on the quality of the carboxylic acid. 
ESI-MS: m/z 437.2 [M]+. The Boc-protected derivative 
was treated with TFA (5ml) for 30 min at room tem-
perature and isolated by evaporation to a solid resi-
due 4 (ESI: m/z 337.2 [M]+).  
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Figure 1. (Scheme 1) Demonstrates the synthesis steps of the N-(2-Aminopropyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5- 
tetrazine-3-yl)benzamide 4 used as diene reaction partner.  
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Synthesis of the [tetracyclo-3,5-dioxo-4-aza-9,12- 
tridecadiene] dienophile (7) compound 
The steps of the synthesis of the dienophile 
compound used for coupling the fullerene are carried 
out as follows: For synthesis of the dienophile com-
pound  7 as educts were used the cyclooctotetraene 
(COT) 5 and maleic anhydride 6 as described in the 
synthesis prescript as follows: The tetracyc-
lo-3,5-dioxo-4-aza-9,12-tridecadiene (TcT), called 
Reppe anhydride 7, was prepared from 4.4 g of 
(1Z,3Z,5Z,7Z)-cycloocta-1,3,5,7-tetraene  5 and 4.4 g 
maleic anhydride 6 in toluene as described by 
Reppe[46] as shown in Figure 2/Scheme 2. 
Ligation of the [tetracyclo-3,5-dioxo-4-aza-9,12- 
tridecadiene] (7) compound with the nitride cluster 
fullerene GdxSc3-xN@C80 
This step describes the chemical modification of 
the nitride cluster fullerene 8. Therefore 
N-1.3.-diamino propane substituted glycine 9 reacts in 
a 1.3. cycoaddition with the fullerene derivative to the 
Boc-protected reaction product 10. Deprotection with 
TFA produces the free amine acting as which after 
reaction with the Reppe anhydride 7 formed the di-
enophile reactant 11, as illustrated later in Figure 4 
/scheme 4.  
The explicit synthesis steps as visualized in Fig-
ure 3/scheme 3, without the last step were conducted 
according the general synthetic strategy documented 
by Kordatos [47]. 
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Figure 2. (Scheme 2)  Illustrates the classical chemical reaction of the cyclooctotetraene (COT) 5 with maleic anhydride 6 
to the resulting reaction product tetracyclo-3,5-dioxo-4-aza-9,12-tridecadiene called “Reppe anhydride” 7 used as di-
enophile reaction partner. 
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Figure 3. (Scheme 3)  Shows the reaction of Reppe anhydride 7 after 1,3-dipolar cycloaddition reaction of the Boc pro-
tected N-1.3.-diamino propane linker substituted glycine 9 with the GdxSc3-xN@C80 8. The product 11 acts as the di-
enophile reaction partner with diene tetrazine-NLS-S
∩S-CPP conjugate 13 in the final DARinv. as pointed out in Figure 
5/scheme 5). 
 Int. J. Med. Sci. 2010, 7 
 
 
http://www.medsci.org 
141
Solid phase peptide synthesis (SPPS) of the NLS and CPP 
peptide modules  
For solid phase syntheses of both, the NLS ad-
dress peptide as well as of the CPP transport peptide, 
we employed the Fmoc-strategy in a fully automated 
multiple synthesizer (Syro II).[39] The synthesis was 
carried out on a 0.05 mmol 
Fmoc-Lys(Boc)-polystyrene resin 1% crosslinked and 
on a 0.053 mmol Fmoc-Cys(Trt)-polystyrene resin (1% 
crosslinked). As coupling agent 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) was used. The last 
amino acid of the NLS-peptide was incorporated as 
Boc-Lys(COT)-OH. Cleavage and deprotection of the 
peptide resin were affected by treatment with 90% 
trifluoroacetic acid, 5% ethanedithiol, 2.5% thioanisol, 
2.5% phenol (v/v/v/v) for 2.5 h at room temperature. 
The products were precipitated in ether. The crude 
material was purified by preparative HPLC on an 
Kromasil 300-5C18 reverse phase column (20 × 150 
mm) using an eluent of 0.1% trifluoroacetic acid in 
water (A) and 60% acetonitrile in water (B). The pep-
tides were eluted with a successive linear gradient of 
25% B to 60% B in 40 min at a flow rate of 20 ml/min. 
The fractions corresponding to the purified peptides 
were lyophilized. 
Ligation of the tetrazine diene compound N-(2-Amino-
propyl)-4-(6-(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)ben
zamide (4) with the NLS-Cys peptide and coupling to the 
Cys-CPP via disulfide bridge formation. 
The tetrazine diene compound 4 was attached to 
the N-terminus of the NLS sequence. Simultaneously 
a cysteine was appended to the C-termini of the NLS 
and the CPP peptides for disulfide bond formation 
between these modules. This enables the intracellular 
enzymatic cleavage and dissociation of the CPP from 
the NLS immediately after the passage into the cy-
toplasm. For the reaction the SH-groups of the 
CPP-Cys and of the tetrazine-NLS-Cys address mod-
ule 12 were oxidized in the range of 2 mg × ml-1 in a 
20% DMSO water solution. Five hours later the reac-
tion was completed. The progress of the oxidation to 
the resulting diene tetrazine-NLS-S
∩S-CPP  13 (as 
shown in Figure 4/scheme 4) was monitored by ana-
lytical C18 reverse phase HPLC. 
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Figure 4. (Scheme 4)  The  resulting  molecule  13 consists of the diene compound ligated by 
N-(2-aminopropyl)-4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazine-3-yl)benzamide linker to nuclear localization sequence (NLS) 
which in turn is covalently connected by disulfide bridge formation with the cysteines of the C-terminus of the cell pene-
trating peptide (CPP) and the NLS. This diene tetrazine-NLS-S
∩S-CPP conjugate 13 was ligated with the functionalized MR 
imaging component GdSc2@C80n cargo 11 (Figure 3/scheme 3).  
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DARinv mediated ligation of the [TcT-N-propyl]-N- 
glycyl-GdSc2@C80n with the N-(2-Aminopropyl)-4-(6- 
(pyrimidine-2-yl)-1,2,4,5-tetrazine-3-yl)benzamide 
(4)-NLS-S
∩S-CPP to the Gd-cluster@-BioShuttle 
Both compounds, the Gd-cluster-fullerene 
GdSc2@C80n linked with the [TcT-N-propyl]-N-glycyl 
dienophile  11 and the diene tetrazine-NLS-S
∩S-CPP 
13 react in stoechiometrically equimolar amounts af-
ter dissolving in aqueous solution and storage at room 
temperature (as illustrated in Figure 5/scheme 5). The 
reaction is complete when the colour has changed 
from magenta to yellow. The Gd-cluster@-BioShuttle 
as a product 14 was isolated by lyophilization. 
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Figure 5. (Scheme 5)  Depicts the Diels Alder inverse as the terminal ligation step to the Gd-cluster@-BioShuttle as final 
product 14 after purification ready for use in MR imaging studies. 
 
Purification the Gd-cluster@-BioShuttle (14) 
After ligation the product 14 was precipitated in 
ether and purified by preparative HPLC (Shimadzu 
LC-8A, Japan) on a YMC ODS-A 7A S-7 µm reverse 
phase column (20 × 250 mm), using 0.1% trifluoroace-
tic acid in water (A) and 60% acetonitrile in water (B) 
as eluent. The conjugate was eluted with a successive 
linear gradient, increasing from 25% to 60% B-eluent 
in 49 min at a flow rate of 10 ml/min. The fractions 
corresponding to the purified conjugate were lyophi-
lized. Sequences of single modules as well as the 
complete bimodular construct were characterized 
with analytical HPLC (Shimadzu LC-10, Japan) using 
a YMC-Pack Pro C18 (150 × 4.6mm ID) S-5µm, 120A 
column with 0.1% trifluoracetic acid in water (A) and 
20% acetonitrile in water (B) as eluent. The analytical 
gradient ranged from 5% (B) to 80% (B) in 35 minutes. 
The constructs were further characterized with laser 
desorption mass spectrometry (Finnigan, Vision 
2000).  
Cell culture 
The human breast cancer cell line MDA-MB-231 
was obtained from the American Type Culture Col-
lection (ATCC). MDA-MB-231 cells were cultured 
routinely in RPMI-1640 (Invitrogen, Karlsruhe, Ger-
many) supplemented with 10% FCS (Beckton & 
Dickinson, Germany). Cell cultures were kept under 
standard conditions (37°C, humidified atmosphere, 
5% CO2) and passaged 2 times a week. 
MRI measurements 
Protocol of the T1 magnetic resonance relaxometry 
Different dilutions of the probes 14 
(Gd-cluster@-BioShuttle) were prepared for T1 MR 
relaxometry of Gd-cluster@-BioShuttle. 
Gd-cluster@-BioShuttle (229 µg) was dissolved in PBS 
containing 2% DMSO resulting in a concentration of 
0.22 mmol/L (0.22 nmol/µL). The stock solution was 
diluted with Hank’s solution to concentrations of 
(0.022 mmol/L) 0.022 nmol/µL, 0.0022 nmol/µL (2.2 
µmol/L) and 0.00022 nmol/µL (and 0.22 µmol/L) 
respectively. The relaxivity was measured in 50 µL of 
each probe. As references 50 µL Hank’s solution con-
taining 2% DMSO and 50 µL of Gd-DTPA (Magne-
vist®, 0.5 nmol/µL [0.5 mmol/L]) were used.  
The MDA-MB-231 cells were incubated with 100 
µL of the respective solutions as well as Hank’s solu-
tion containing 2% DMSO as a control. After 25 min-
utes, the solutions were removed from the cells, then 
cells were washed twice with Hank’s solution and 
kept in Hank’s solution containing 2% DMSO. 
The T1 MR relaxometry measurememts in a 
gelatine phantom of Gd-cluster@-BioShuttle in gela-
tine were performed with a saturation recovery turbo 
FLASH pulse sequence with different saturation re-
covery delays TI of 90, 200, 400, 800, 1200, 2000, 4000, 
and 7000 ms. The other imaging parameters were: TR Int. J. Med. Sci. 2010, 7 
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= 7160 ms; TE = 1,67 ms, 1 average; FOV = 150 mm; 
slice thickness = 4.5 mm; voxel size = 1.2 × 1.2 × 4.5 
mm3). From the series of images T1 relaxation times 
were calculated by a non-linear fit (Leven-
berg-Marquardt algorithm) of the signal amplitudes 
using the exponential saturation recovery relation-
ship.  
In the MDA-MB-231 cells morphologic MRI was 
carried out using a T1-weighted gradient echo se-
quence (TR, 600 ms; TE, 14 ms; averages, 3; FOV, 180 × 
73 mm; slice thickness, 1.5 mm; flip angle, 90°), and a 
T2-weighted turbo spin echo sequence (TR, 1,070 ms; 
TE, 14 ms; average, 3; FOV, 180 × 73 mm; matrix, 256; 
slice thickness, 2 mm). 
Cell viability 
Human MDA-MB-231 breast adenocarcinoma 
cells were incubated with the Gd-cluster@-BioShuttle 
14 in a concentration of 0.5 mM) for 24, 48, and 72 
hours. Untreated cells served as controls for the same 
time periods. The cell viability was assessed by a dye 
exclusion assay with trypan blue staining (0.4%) for 5 
minutes. This dye exclusion assay is useful for a quick 
decision of cell toxicity. If an influence of the drug 
Gd-cluster@-BioShuttle on cell viability would be ob-
served, a more sensitive assays for quantification like 
the MTT assay or flow cytometry could be used. Here 
we did not find a difference in the cellular phenotype 
between treated (0.5mM) and untreated control cells 
with the trypan blue assay. 
Results and Discussion 
We could not find a difference with dye exclu-
sion assay between the control cells and the ni-
tride-cluster endo-fullerenes treated cells until 72 
hours. 
Within this manuscript we would first like to il-
lustrate the different chemical procedures in close 
context with 1. the solide phase peptide synthesis by 
Merrifield combined with 2. the protection group 
technology by Carpino for the synthesis of functional 
peptides, and 3. the synthesis of the nitride-cluster 
endo-fullerenes [GdxSc3-xN@C80  (x = 1, 2)] by the 
Kraetschmer-Huffmann DC arc-discharge method 
modified by Dunsch under addition of NH3. 4. The 
synthesized components were combined using the 
Diels Alder Reaction inverse as an efficient ligation 
method for coupling the functional peptides as well as 
the nitride-cluster endo-fullerenes as a cargo. The 
second intention within this manuscript was to con-
sider the MRI-measurements, described below as a 
basis for determining MRI tomographical signals in 
comparison to the commonly used MRI contrast agent 
(CA) Gd-DTPA. 
MRI-Measurements in MDA-MB-231 breast ade-
nocarcinoma cells 
Recently, an endo-fullerene PEG- and hy-
droxy-functionalyzed [48], but no endo-fullerenes 
harbouring functionalizations of the 
Gd-cluster@-BioShuttles described in our manuscript, 
were documented. 
In our measurements the concentrations of the 
Gd-cluster@-BioShuttle  14 5 µmol Gd/kg were 
equivalent to 1/20 of a typical clinical dose (100 µmol 
Gd/kg) of Gd-DTPA. 
In morphological T2 and T1 weighted sequences, 
Gd-cluster@-BioShuttle diluted 1:100 (0.0022 nmol/µL 
ؙ 2.2 µM) and 1 : 1000 (0.00022 nmol/µL ؙ 0.2 µ) ap-
peared more hyperintense than the stock solution (0.2 
nmol/µL) and the preceding dilution 1 : 10 which 
shows an averaged relaxation time slightly decreased 
from 1126.9 to 1101.1 ms. This finding corresponds to 
the quantification of T1 relaxation times, which was 
highest when Gd-cluster@-BioShuttle was diluted 
1:1000 (T1 relaxation time of 1758 ms). For compari-
son, in 0.5 nmol/µL Gd-DTPA (Magnevist) a T1 re-
laxation time of 1090.5 ms was determined. 
In advance: The way from a MRI tomographical 
signal is still far from a contrast agent in MRI. The first 
measurements could demonstrate: As shown here, 
our new intracellular MRI contrast agent (CA) could 
be a promising solution: We coupled a nitride-cluster 
endo-fullerene [GdxSc3-xN@C80  (x = 1, 2)] to the 
BioShuttle delivery system resulting in the 
Gd-cluster@-BioShuttle 14. It was used to investigate 
whether an intracellular MR imaging is possible and 
to estimate the T1 relaxivity on MR (1.5 T).  
Historically already in 1994 elec-
tron-spin-resonance and mass-spectrometry studies of 
metallofullerenes were documented by the Dunsch 
group and seemed to suggest a certain potential of 
metallofullerenes as appropriate candidates as MRI 
contrast agents.[49] Further MRI studies revealed a 
high proton relaxivity of Gd-fullerenols and a high 
signal enhancement at lower Gd concentrations [50] 
compared to the concentration of the commonly used 
Gd-DTPA [51] and other CAs like the Gd-BOPTA 
chelate gadobutrol [52] was documented. In our ex-
periments we could confirm these MRI signal data in 
MDA-MB-231 breast cancer cells after incubation with 
the new CA Gd-cluster@-BioShuttle and like to point 
out that the investigated Gd-cluster@-BioShuttle di-
verges from the properties of the Gd-fullerenol de-
veloped by the Mikawa group. The former molecule is 
characterized by surface functionalization with hy-
droxyl groups, responsible for the water solubility, 
our molecule followed new strategies to circumvent 
the insolubility of fullerenes in biological fluids with Int. J. Med. Sc
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Outlook 
For stereotactical biopsies a contrast enhanced 
MRI with high spatial resolution is indispensable and 
depends on the increased signal intensity in observa-
tion of neo-angiogenesis, proliferation of endothelial 
cells [58] or of tumor tissue.[59] This difference in 
signal intensity between tumor cells and the interfaces 
of the surrounding healthy tissue is difficult to meas-
ure at present.[58] In general a good characterization 
o f  t i s s u e  b y  w i d e l y  u s e d  ‘ o l d  f a s h i o n e d ’  
Gd-complexes like Gd-DTPA is hardly possible. A 
determination of the distribution of grey-values and 
differential relaxation times are unsatisfactory so far, 
because radiation induced necrosis [58], vital tumor 
tissue and cerebral metastases are nearly undistin-
guishable.[51] Additionally, preclinical data suggest 
nephrotoxic properties induced by the commonly 
used Gd-based contrast media which hamper its use 
as an intracellular contrast agent.[60-62] Therefore a 
progress in the precision of therapy like the inten-
sity-modulated radiation therapy (IMRT) and the use 
of heavy ions demands absolute reliability of new 
diagnostics and treatment planning for prostate and 
brain tumors. By the fact that the rare earth metals 
trapped inside of the carbon cage are isolated from the 
environment, the endo-metallofullerenes like the 
GdSc2@C80 8 could be considered as ideal MRI con-
trast agents qualified for Molecular Imaging in MRT. 
Here we are at the beginning to evaluate the possi-
bilities arising in the Molecular Imaging world. 
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